表紙
市場調査レポート

重症虚血肢:パイプライン製品の分析

Critical Limb Ischemia - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 219779
出版日 ページ情報 英文 150 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
重症虚血肢:パイプライン製品の分析 Critical Limb Ischemia - Pipeline Review, H1 2016
出版日: 2016年05月18日 ページ情報: 英文 150 Pages
概要

重症虚血肢は、末梢動脈疾患(PAD)のなかで最も重篤な症状です。アテローム性動脈硬化症に関連した慢性的な炎症過程が原因となっています。主な症状には、足・つま先の痛みやしびれ、ただれ、皮膚感染症などがありますが、どれも発症後は治療不可能なものです。この疾患の治療目的は、冠動脈へのリスク要因の軽減(禁煙、コレステロール軽減など)や、疼痛の軽減、潰瘍の治癒、切断手術の回避、生活の質(QoL)の改善、生存率の向上などとなっています。

当レポートでは、世界各国での重症虚血肢(CLI)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

重症虚血肢の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

重症虚血肢:企業で開発中の治療薬

重症虚血肢:大学/機関で研究中の治療薬

重症虚血肢:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

重症虚血肢:企業で開発中の製品

重症虚血肢:大学/機関で研究中の製品

重症虚血肢の治療薬開発に従事している企業

  • AnGes MG, Inc.
  • Apceth GmbH & Co. KG
  • Athersys, Inc.
  • Caladrius Biosciences, Inc.
  • Cynata Therapeutics Limited
  • Hemostemix Ltd
  • Histocell S.L.
  • ID Pharma Co., Ltd.
  • IntelliCell BioSciences Inc.
  • Juventas Therapeutics, Inc.
  • Kasiak Research Private Limited
  • 興和
  • Multi Gene Vascular Systems Ltd
  • Pharmicell Co., Ltd.
  • Pluristem Therapeutics Inc.
  • ReNeuron Group Plc
  • Stempeutics Research Private Limited
  • Targazyme, Inc.
  • TikoMed AB
  • U.S. Stem Cell, Inc.
  • Vericel Corporation
  • ViroMed Co., Ltd.

重症虚血肢:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

重症虚血肢:最近のパイプライン動向

重症虚血肢:休止中のプロジェクト

重症虚血肢:開発が中止された製品

重症虚血肢:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8035IDB

Summary

Global Markets Direct's, 'Critical Limb Ischemia - Pipeline Review, H1 2016', provides an overview of the Critical Limb Ischemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Critical Limb Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia
  • The report reviews pipeline therapeutics for Critical Limb Ischemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Critical Limb Ischemia therapeutics and enlists all their major and minor projects
  • The report assesses Critical Limb Ischemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Critical Limb Ischemia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Critical Limb Ischemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Critical Limb Ischemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Critical Limb Ischemia Overview
  • Therapeutics Development
    • Pipeline Products for Critical Limb Ischemia - Overview
    • Pipeline Products for Critical Limb Ischemia - Comparative Analysis
  • Critical Limb Ischemia - Therapeutics under Development by Companies
  • Critical Limb Ischemia - Therapeutics under Investigation by Universities/Institutes
  • Critical Limb Ischemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Critical Limb Ischemia - Products under Development by Companies
  • Critical Limb Ischemia - Products under Investigation by Universities/Institutes
  • Critical Limb Ischemia - Companies Involved in Therapeutics Development
    • AnGes MG, Inc.
    • Apceth GmbH & Co. KG
    • Athersys, Inc.
    • Caladrius Biosciences, Inc.
    • Cynata Therapeutics Limited
    • Hemostemix Ltd
    • Histocell S.L.
    • ID Pharma Co., Ltd.
    • IntelliCell BioSciences Inc.
    • Juventas Therapeutics, Inc.
    • Kasiak Research Private Limited
    • Kowa Company, Ltd.
    • Multi Gene Vascular Systems Ltd
    • Pharmicell Co., Ltd.
    • Pluristem Therapeutics Inc.
    • ReNeuron Group Plc
    • Stempeutics Research Private Limited
    • Targazyme, Inc.
    • TikoMed AB
    • U.S. Stem Cell, Inc.
    • Vericel Corporation
    • ViroMed Co., Ltd.
  • Critical Limb Ischemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACP-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AdipoCell - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Alecmestencel-T - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASCT-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • beperminogene perplasmid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biologic to Activate FGF2 for Critical Limb Ischemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellgram-CLI - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CLBS-12 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DVC-10101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Critical Limb Ischemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HC-016 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ixmyelocel-T - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JVS-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MultiGeneAngio - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PF-05285401 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pitavastatin NP - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PLX-PAD - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Protein to Agonize LRP5 and LRP6 for Critical Limb Ischemia and Myocardial Infarction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Refacell-CLI - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Rejuveinix - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ReN-009 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Cardiovacular Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell therapy for CNS, CVS, Dermatological, Immunological and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Critical Limb Ischemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Critical Limb Ischemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Critical Limb Ischemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stempeucel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TM-700 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TXA-302 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TZ-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VM-202 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Critical Limb Ischemia - Recent Pipeline Updates
  • Critical Limb Ischemia - Dormant Projects
  • Critical Limb Ischemia - Discontinued Products
  • Critical Limb Ischemia - Product Development Milestones
    • Featured News & Press Releases
      • Apr 18, 2016: Hemostemix Receives IRB Approval from the Houston Methodist Hospital Research Institute and the University of California Los Angeles
      • Apr 18, 2016: Caladrius Reaches Agreement with Japanese Regulators on Development Plan for CD34 Cell Therapy for Critical Limb Ischemia
      • Jan 22, 2016: ViroMed Publishes Results from Critical Limb Ischemia Phase II Clinical Study
      • Dec 22, 2015: Hemostemix Poised to Expand Phase-2 Clinical Trial of Lead Product ACP-01 to the United States
      • Dec 21, 2015: Pluristem Reaches Agreement with Japan's PMDA on Protocol for Final Trial Targeting Market Entry via Accelerated Pathway
      • Oct 05, 2015: Hemostemix to Present at 2015 Stem Cell Meeting on the Mesa
      • Sep 14, 2015: Hemostemix Executes Strategic Alliance with Hemostemix Asia for Expansion of Phase-2 Clinical Trial to Taiwan
      • Aug 17, 2015: Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications
      • Aug 12, 2015: Patient Enrollment Begins in Europe in the Global Phase III Clinical Trial of HGF Gene Therapy for Critical Limb Ischemia
      • Aug 12, 2015: Japan Grants Safety Clearance to Pluristem's PLX-PAD Cells for Use in Clinical Trials
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Critical Limb Ischemia, H1 2016
  • Number of Products under Development for Critical Limb Ischemia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Critical Limb Ischemia - Pipeline by AnGes MG, Inc., H1 2016
  • Critical Limb Ischemia - Pipeline by Apceth GmbH & Co. KG, H1 2016
  • Critical Limb Ischemia - Pipeline by Athersys, Inc., H1 2016
  • Critical Limb Ischemia - Pipeline by Caladrius Biosciences, Inc. , H1 2016
  • Critical Limb Ischemia - Pipeline by Cynata Therapeutics Limited, H1 2016
  • Critical Limb Ischemia - Pipeline by Hemostemix Ltd, H1 2016
  • Critical Limb Ischemia - Pipeline by Histocell S.L., H1 2016
  • Critical Limb Ischemia - Pipeline by ID Pharma Co., Ltd., H1 2016
  • Critical Limb Ischemia - Pipeline by IntelliCell BioSciences Inc., H1 2016
  • Critical Limb Ischemia - Pipeline by Juventas Therapeutics, Inc., H1 2016
  • Critical Limb Ischemia - Pipeline by Kasiak Research Private Limited, H1 2016
  • Critical Limb Ischemia - Pipeline by Kowa Company, Ltd., H1 2016
  • Critical Limb Ischemia - Pipeline by Multi Gene Vascular Systems Ltd, H1 2016
  • Critical Limb Ischemia - Pipeline by Pharmicell Co., Ltd., H1 2016
  • Critical Limb Ischemia - Pipeline by Pluristem Therapeutics Inc., H1 2016
  • Critical Limb Ischemia - Pipeline by ReNeuron Group Plc, H1 2016
  • Critical Limb Ischemia - Pipeline by Stempeutics Research Private Limited, H1 2016
  • Critical Limb Ischemia - Pipeline by Targazyme, Inc., H1 2016
  • Critical Limb Ischemia - Pipeline by TikoMed AB, H1 2016
  • Critical Limb Ischemia - Pipeline by U.S. Stem Cell, Inc., H1 2016
  • Critical Limb Ischemia - Pipeline by Vericel Corporation, H1 2016
  • Critical Limb Ischemia - Pipeline by ViroMed Co., Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Critical Limb Ischemia Therapeutics - Recent Pipeline Updates, H1 2016
  • Critical Limb Ischemia - Dormant Projects, H1 2016
  • Critical Limb Ischemia - Dormant Projects (Contd..1), H1 2016
  • Critical Limb Ischemia - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Critical Limb Ischemia, H1 2016
  • Number of Products under Development for Critical Limb Ischemia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top